首页 > 最新文献

Journal of immunological methods最新文献

英文 中文
Complete primer set for amplification and expression of full-length recombinant human monoclonal antibodies from single human B cells
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2025-01-31 DOI: 10.1016/j.jim.2025.113823
Sachin Kushwaha , Varsha Jawahar , Ajay Kumar , Lauren Griffin , Thomas L. Rothstein , Devinder Sehgal , Naeem Khan
Human monoclonal antibodies (mAbs) are an important segment in precision therapeutics. Various methodologies are available for generating them. Recombinant human mAbs expression from sorted single B cells is preferred for its rapid expression using mammalian vectors while maintaining in vivo immunoglobulin (Ig) pairing. The success rate of generating recombinant mAbs from single sorted human B cells directly relies on Ig heavy (IgH) and light (IgL) gene coverage of the PCR primers. Existing primer sets fail to cover all functional human Ig gene rearrangements, exhibit high degeneracy leading to non-specific amplifications and mutations arising from primer mismatch/degeneracy, and require high amplification cycles. Some existing primer sets have high coverage but are not designed for expression as recombinant mAbs. Here, we have designed a primer set to amplify all functional V(D)J transcripts in human B cell repertoire using a nested RT-PCR approach. The resultant amplicons can be cloned into mammalian vectors for expression of recombinant mAb. Non-specific amplifications were minimized using isotype-specific primers for cDNA synthesis and limiting primer degeneracy. We validated the designed primers on single sorted B cells, bulk sorted B cells and peripheral blood mononuclear cells. We were successfully able to amplify paired heavy and light chain transcripts in 38.46 % (80/208) from naive, memory and B1 B cell subsets sorted as single B cells. Paired Ig transcripts from five single B cells were cloned into expression vectors and purified from mammalian cells as recombinant mAbs. Thus, our new primer set offers significant advantages over existing primers as it allows amplification of all functional V(D)J rearrangements, facilitating rapid generation of antigen-specific recombinant antibodies from diverse human B cell repertoires following vaccinations and infections previously inaccessible due to primer limitations.
{"title":"Complete primer set for amplification and expression of full-length recombinant human monoclonal antibodies from single human B cells","authors":"Sachin Kushwaha ,&nbsp;Varsha Jawahar ,&nbsp;Ajay Kumar ,&nbsp;Lauren Griffin ,&nbsp;Thomas L. Rothstein ,&nbsp;Devinder Sehgal ,&nbsp;Naeem Khan","doi":"10.1016/j.jim.2025.113823","DOIUrl":"10.1016/j.jim.2025.113823","url":null,"abstract":"<div><div>Human monoclonal antibodies (mAbs) are an important segment in precision therapeutics. Various methodologies are available for generating them. Recombinant human mAbs expression from sorted single B cells is preferred for its rapid expression using mammalian vectors while maintaining in vivo immunoglobulin (Ig) pairing. The success rate of generating recombinant mAbs from single sorted human B cells directly relies on Ig heavy (IgH) and light (IgL) gene coverage of the PCR primers. Existing primer sets fail to cover all functional human Ig gene rearrangements, exhibit high degeneracy leading to non-specific amplifications and mutations arising from primer mismatch/degeneracy, and require high amplification cycles. Some existing primer sets have high coverage but are not designed for expression as recombinant mAbs. Here, we have designed a primer set to amplify all functional V(<em>D</em>)J transcripts in human B cell repertoire using a nested RT-PCR approach. The resultant amplicons can be cloned into mammalian vectors for expression of recombinant mAb. Non-specific amplifications were minimized using isotype-specific primers for cDNA synthesis and limiting primer degeneracy. We validated the designed primers on single sorted B cells, bulk sorted B cells and peripheral blood mononuclear cells. We were successfully able to amplify paired heavy and light chain transcripts in 38.46 % (80/208) from naive, memory and B1 B cell subsets sorted as single B cells. Paired Ig transcripts from five single B cells were cloned into expression vectors and purified from mammalian cells as recombinant mAbs. Thus, our new primer set offers significant advantages over existing primers as it allows amplification of all functional V(<em>D</em>)J rearrangements, facilitating rapid generation of antigen-specific recombinant antibodies from diverse human B cell repertoires following vaccinations and infections previously inaccessible due to primer limitations.</div></div>","PeriodicalId":16000,"journal":{"name":"Journal of immunological methods","volume":"538 ","pages":"Article 113823"},"PeriodicalIF":1.6,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges for complement functional assays in the clinical laboratory: From test validation to clinical interpretation
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2025-01-23 DOI: 10.1016/j.jim.2025.113814
Vijayalakshmi Nandakumar , Karin M.P. Braun , Maria Alice V. Willrich
Complement functional assays are essential first-tier tests for a gamut of disorders spanning from inborn errors of the immune system which lead to recurrent severe infections, to angioedema attacks, presentation of autoimmune disease, thrombotic microangiopathies and rare kidney disorders. These assays evaluate the activity of the three complement pathways and specific complement components, which helps in differential diagnosis and monitoring disease progression. The rising use of complement inhibitors for treating complement-mediated thrombotic microangiopathies has heightened the demand for personalized treatment plans and laboratory assessment of complement blockage. However, conducting these assays is challenging due to the labile nature of complement proteins, which necessitates strict handling protocols—prompt processing, cold centrifugation, and preferable storage at −80 °C. Currently, the only FDA-approved complement functional test is the classical pathway activity assay while other tests are categorized as laboratory developed tests (LDTs). Validation of LDTs requires thorough evaluation of precision, accuracy, reference intervals, clinical reportable ranges, analytical sensitivity, and specificity. Achieving harmonization across laboratories is critical but heavily relies on the methodologies and calibrators used. This article discusses the various challenges and limitations associated with complement functional assays, highlighting the need for standardization and improved practices in clinical laboratories.
{"title":"Challenges for complement functional assays in the clinical laboratory: From test validation to clinical interpretation","authors":"Vijayalakshmi Nandakumar ,&nbsp;Karin M.P. Braun ,&nbsp;Maria Alice V. Willrich","doi":"10.1016/j.jim.2025.113814","DOIUrl":"10.1016/j.jim.2025.113814","url":null,"abstract":"<div><div>Complement functional assays are essential first-tier tests for a gamut of disorders spanning from inborn errors of the immune system which lead to recurrent severe infections, to angioedema attacks, presentation of autoimmune disease, thrombotic microangiopathies and rare kidney disorders. These assays evaluate the activity of the three complement pathways and specific complement components, which helps in differential diagnosis and monitoring disease progression. The rising use of complement inhibitors for treating complement-mediated thrombotic microangiopathies has heightened the demand for personalized treatment plans and laboratory assessment of complement blockage. However, conducting these assays is challenging due to the labile nature of complement proteins, which necessitates strict handling protocols—prompt processing, cold centrifugation, and preferable storage at −80 °C. Currently, the only FDA-approved complement functional test is the classical pathway activity assay while other tests are categorized as laboratory developed tests (LDTs). Validation of LDTs requires thorough evaluation of precision, accuracy, reference intervals, clinical reportable ranges, analytical sensitivity, and specificity. Achieving harmonization across laboratories is critical but heavily relies on the methodologies and calibrators used. This article discusses the various challenges and limitations associated with complement functional assays, highlighting the need for standardization and improved practices in clinical laboratories.</div></div>","PeriodicalId":16000,"journal":{"name":"Journal of immunological methods","volume":"538 ","pages":"Article 113814"},"PeriodicalIF":1.6,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143039050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peptide fibrils as a vaccine: Proof of concept 肽原纤维作为疫苗:概念证明。
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2025-01-19 DOI: 10.1016/j.jim.2025.113811
Yana Zabrodskaya , Konstantin Sivak , Maria Sergeeva , Andrey Aleksandrov , Elena Kalinina , Aleksandr Taraskin , Mikhail Eropkin , Elena Eropkina , Vladimir Egorov

Background

Rapid vaccine platforms development is crucial for responding to epidemics and pandemics of emerging infectious diseases, such as Ebola. This study explores the potential of peptide vaccines that self-organize into amyloid-like fibrils, aiming to enhance immunogenicity while considering safety and cross-reactivity.

Methods

We synthesized two peptides, G33 and G31, corresponding to a segment of the Ebola virus GP2 protein, with G33 known to form amyloid-like fibrils. Their toxicity was assessed in vitro using an MTT assay on MDCK and A549 cell cultures. For in vivo studies, balb/c mice were immunized with these peptides. Immunogenicity was gauged by ELISA for specific antibodies against the recombinant eGP protein. Hematological parameters were determined, and histopathological changes in organs were documented post-euthanasia.

Results

Both peptides exhibited no cytotoxicity up to 500 μg/mL. G33-immunized mice developed higher antibody titers than those receiving G31 or control, without significant alterations in hematological profiles. However, histological analysis showed periportal infiltration and lymphoid-macrophage clusters in the liver and kidneys, suggesting immune response activation. The homology between the G33 peptide and mammalian proteins poses risks of cross-reactivity.

Conclusion

The amyloid-like fibrils formed by the G33 peptide elicited a stronger immune response without significant hematological changes, underlining the feasibility of fibril-based peptide vaccines. However, the potential for autoimmune responses due to molecular mimicry warrants further investigation before clinical applications can be considered.
背景:快速开发疫苗平台对于应对流行病和埃博拉等新发传染病的大流行至关重要。本研究探索自组织成淀粉样原纤维的肽疫苗的潜力,旨在增强免疫原性,同时考虑安全性和交叉反应性。方法:我们合成了两个肽,G33和G31,对应于埃博拉病毒GP2蛋白的一个片段,其中G33已知形成淀粉样原纤维。用MTT法对MDCK和A549细胞培养物进行体外毒性评估。在体内研究中,用这些肽免疫balb/c小鼠。ELISA检测重组eGP蛋白特异性抗体的免疫原性。测定血液学参数,并记录安乐死后器官的组织病理学变化。结果:两种多肽在浓度为500 μg/ml时均无细胞毒性。g33免疫小鼠的抗体滴度高于G31免疫小鼠或对照组,血液学特征没有明显改变。然而,组织学分析显示门静脉周围浸润和淋巴-巨噬细胞聚集在肝脏和肾脏,提示免疫反应激活。G33肽与哺乳动物蛋白的同源性存在交叉反应的风险。结论:G33肽形成的淀粉样原纤维可引起更强的免疫应答,且无明显血液学变化,说明基于原纤维的肽疫苗是可行的。然而,在考虑临床应用之前,分子模拟引起自身免疫反应的可能性需要进一步研究。
{"title":"Peptide fibrils as a vaccine: Proof of concept","authors":"Yana Zabrodskaya ,&nbsp;Konstantin Sivak ,&nbsp;Maria Sergeeva ,&nbsp;Andrey Aleksandrov ,&nbsp;Elena Kalinina ,&nbsp;Aleksandr Taraskin ,&nbsp;Mikhail Eropkin ,&nbsp;Elena Eropkina ,&nbsp;Vladimir Egorov","doi":"10.1016/j.jim.2025.113811","DOIUrl":"10.1016/j.jim.2025.113811","url":null,"abstract":"<div><h3>Background</h3><div>Rapid vaccine platforms development is crucial for responding to epidemics and pandemics of emerging infectious diseases, such as Ebola. This study explores the potential of peptide vaccines that self-organize into amyloid-like fibrils, aiming to enhance immunogenicity while considering safety and cross-reactivity.</div></div><div><h3>Methods</h3><div>We synthesized two peptides, G33 and G31, corresponding to a segment of the Ebola virus GP2 protein, with G33 known to form amyloid-like fibrils. Their toxicity was assessed in vitro using an MTT assay on MDCK and A549 cell cultures. For in vivo studies, balb/c mice were immunized with these peptides. Immunogenicity was gauged by ELISA for specific antibodies against the recombinant eGP protein. Hematological parameters were determined, and histopathological changes in organs were documented post-euthanasia.</div></div><div><h3>Results</h3><div>Both peptides exhibited no cytotoxicity up to 500 μg/mL. G33-immunized mice developed higher antibody titers than those receiving G31 or control, without significant alterations in hematological profiles. However, histological analysis showed periportal infiltration and lymphoid-macrophage clusters in the liver and kidneys, suggesting immune response activation. The homology between the G33 peptide and mammalian proteins poses risks of cross-reactivity.</div></div><div><h3>Conclusion</h3><div>The amyloid-like fibrils formed by the G33 peptide elicited a stronger immune response without significant hematological changes, underlining the feasibility of fibril-based peptide vaccines. However, the potential for autoimmune responses due to molecular mimicry warrants further investigation before clinical applications can be considered.</div></div>","PeriodicalId":16000,"journal":{"name":"Journal of immunological methods","volume":"538 ","pages":"Article 113811"},"PeriodicalIF":1.6,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expression of bluetongue virus full-length VP7 protein in insect cells and its diagnostic utility for detection of antibodies to the virus infection 蓝舌病病毒全长VP7蛋白在昆虫细胞中的表达及其在病毒感染抗体检测中的诊断价值
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2025-01-15 DOI: 10.1016/j.jim.2025.113801
Sanchay Kumar Biswas , Madhusudan Hosamani , Karam Chand , Ankita Chauhan , Kurat Ul Ain , Vanitha Selvarajan , Sushmita Nautiyal , Muzamil Bashir , Divakar Hemadri , Gaurav Kumar Sharma , B.P. Sreenivasa
Bluetongue (BT) is a vector-borne viral disease of multiple domestic and wild ruminants across the globe. The VP7 protein of bluetongue virus (BTV) is the major immune-dominant structural protein that is conserved across the BTV serotypes and therefore, targeted for the development of immuno-diagnostics for BT. In this study, full-length recombinant VP7 protein (rVP7) of BTV-1 was expressed in Trochoplusia ni derived insect cells (Tn5) using codon-optimized synthetic gene construct through baculovirus expression system. The seed stock of recombinant baculovirus was amplified to a high titre (>1 × 108 pfu/ml) at P2 and P3 in sf9 cells. The rVP7 was successfully produced and purified from infected Tn5 culture lysate for evaluation of the immuno-reactivity and its diagnostic potential. The purified protein showed strong reactivity in western blot analysis with the polyclonal immune serum produced against BTV core antigen in guinea pigs. An indirect ELISA (iELISA) was optimized by using the purified rVP7 for the detection of the group-specific antibodies to BTV in sheep and goats. The iELISA was found to be highly sensitive (98.9 %), specific (98.1 %), and reproducible (CV < 10 %) for detection of the antibodies to BTV in sheep and goat serum. The iELISA could detect the specific antibodies in naturally infected goat serum containing type-specific neutralizing antibodies to different BTV serotypes indicating the potential of the rVP7 for the development of the group-specific sero-diagnostics for BT.
蓝舌病是一种在全球多种家养和野生反刍动物中传播的媒介传播的病毒性疾病。蓝舌病毒(BTV)的VP7蛋白是主要的免疫显性结构蛋白,在BTV血清型中具有保守性,因此可以用于BT的免疫诊断。本研究通过杆状病毒表达系统,利用密码子优化的合成基因构建,在ni Trochoplusia衍生的昆虫细胞(Tn5)中表达了BTV-1的全长重组VP7蛋白(rVP7)。重组杆状病毒种子库在sf9细胞P2和P3处扩增到高滴度(>1 × 108 pfu/ml)。从感染的Tn5培养液中成功制备并纯化了rVP7,以评估其免疫反应性及其诊断潜力。纯化后的蛋白与豚鼠抗BTV核心抗原的多克隆免疫血清具有较强的免疫反应性。用纯化的rVP7优化间接ELISA (iELISA)检测绵羊和山羊BTV群体特异性抗体。发现iELISA具有高灵敏度(98.9 %)、特异性(98.1 %)和重复性(CV)
{"title":"Expression of bluetongue virus full-length VP7 protein in insect cells and its diagnostic utility for detection of antibodies to the virus infection","authors":"Sanchay Kumar Biswas ,&nbsp;Madhusudan Hosamani ,&nbsp;Karam Chand ,&nbsp;Ankita Chauhan ,&nbsp;Kurat Ul Ain ,&nbsp;Vanitha Selvarajan ,&nbsp;Sushmita Nautiyal ,&nbsp;Muzamil Bashir ,&nbsp;Divakar Hemadri ,&nbsp;Gaurav Kumar Sharma ,&nbsp;B.P. Sreenivasa","doi":"10.1016/j.jim.2025.113801","DOIUrl":"10.1016/j.jim.2025.113801","url":null,"abstract":"<div><div>Bluetongue (BT) is a vector-borne viral disease of multiple domestic and wild ruminants across the globe. The VP7 protein of bluetongue virus (BTV) is the major immune-dominant structural protein that is conserved across the BTV serotypes and therefore, targeted for the development of immuno-diagnostics for BT. In this study, full-length recombinant VP7 protein (rVP7) of BTV-1 was expressed in <em>Trochoplusia ni</em> derived insect cells (Tn5) using codon-optimized synthetic gene construct through baculovirus expression system. The seed stock of recombinant baculovirus was amplified to a high titre (&gt;1 × 10<sup>8</sup> pfu/ml) at P2 and P3 in sf9 cells. The rVP7 was successfully produced and purified from infected Tn5 culture lysate for evaluation of the immuno-reactivity and its diagnostic potential. The purified protein showed strong reactivity in western blot analysis with the polyclonal immune serum produced against BTV core antigen in guinea pigs. An indirect ELISA (iELISA) was optimized by using the purified rVP7 for the detection of the group-specific antibodies to BTV in sheep and goats. The iELISA was found to be highly sensitive (98.9 %), specific (98.1 %), and reproducible (CV &lt; 10 %) for detection of the antibodies to BTV in sheep and goat serum. The iELISA could detect the specific antibodies in naturally infected goat serum containing type-specific neutralizing antibodies to different BTV serotypes indicating the potential of the rVP7 for the development of the group-specific sero-diagnostics for BT.</div></div>","PeriodicalId":16000,"journal":{"name":"Journal of immunological methods","volume":"538 ","pages":"Article 113801"},"PeriodicalIF":1.6,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of self-collected dried blood spots for detection of SARS-CoV-2 nucleocapsid antibodies shows low sensitivity 自采干血斑点检测SARS-CoV-2核衣壳抗体敏感性低。
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2025-01-01 DOI: 10.1016/j.jim.2024.113800
Thomas Egger , Tamara Dörr , Reto Thoma , Susanne Nigg , Lorenz Risch , Alessio Cremonesi , Pietro Vernazza , Philipp Kohler , Christian R. Kahlert

Background and aims

Dried blood spots (DBS) have been proposed as a cost-effective surveillance method for population-wide screening of SARS-CoV-2 immunity but sensitivity of DBS based on self-collected DBS samples is unknown. To evaluate the success of vaccination strategies, it is necessary to differentiate vaccination from natural infection. Therefore, a test for antibodies against the viral nucleocapsid protein (anti-N) is desirable.

Materials and methods

In our prospectively followed cohort of healthcare workers (HCW) in eastern Switzerland, we assessed SARS-CoV-2-anti-N-seroprevalence using DBS on a biweekly basis from March to September 2020. Phlebotomy samples were collected in March and September and tested for anti-N-seropositivity, as well as SARS-CoV-2 spike antibodies for quantitative validation. Venous antibody testing was compared with DBS results for anti-N using the Roche Elecsys electro-chemiluminescence immunoassay.

Results

792 HCW (median age 38.3 years) were included, 35 (4.4 %) were SARS-CoV-2-anti-N-seropositive. Of 43 matching DBS, 25 tested positive for anti-N, accounting for a sensitivity of 58.1 % (95 %CI 43.3–71.6 %). We found a significant correlation of anti-N from DBS with results from phlebotomy samples (r = 0.77;p < 0.0001), with higher levels being associated with a higher true-positive rate. Anti-N in DBS correlated significantly with quantitatively validated anti-S obtained from serum (r = 0.67;p < 0.0001).

Conclusion

Although home DBS collection was feasible in a larger cohort and we found a high correlation between anti-N detection in DBS and phlebotomy samples, the sensitivity of self-collected DBS samples was significantly impaired for the Roche Elecsys anti-N assay. Therefore, we cannot recommend this method for DBS when testing from venous blood is possible.
背景和目的:干血点(DBS)已被提出作为一种具有成本效益的监测方法,用于筛查人群对SARS-CoV-2的免疫,但基于自行采集的DBS样本的DBS敏感性尚不清楚。为了评估疫苗接种策略的成功与否,有必要将疫苗接种与自然感染区分开来。因此,需要对病毒核衣壳蛋白(anti-N)进行抗体检测。材料和方法:在瑞士东部前瞻性随访的医护人员(HCW)队列中,我们从2020年3月至9月每两周使用DBS评估sars - cov -2抗n血清阳性率。3月和9月采集血样,检测抗n血清阳性,以及SARS-CoV-2刺突抗体进行定量验证。采用罗氏Elecsys电化学发光免疫分析法将静脉抗体检测与DBS结果进行比较。结果:纳入792例HCW,中位年龄38.3岁,35例(4.4%)sars - cov -2抗n血清阳性。在43例匹配的DBS中,25例检测出抗n阳性,敏感性为58.1% (95% CI为43.3- 71.6%)。结论:尽管在更大的队列中,家庭DBS采集是可行的,并且我们发现DBS中抗n检测与采血样本之间存在高度相关性,但自行采集的DBS样本对罗氏Elecsys抗n检测的敏感性明显受损。因此,当可以从静脉血中进行测试时,我们不推荐这种方法用于DBS。
{"title":"Evaluation of self-collected dried blood spots for detection of SARS-CoV-2 nucleocapsid antibodies shows low sensitivity","authors":"Thomas Egger ,&nbsp;Tamara Dörr ,&nbsp;Reto Thoma ,&nbsp;Susanne Nigg ,&nbsp;Lorenz Risch ,&nbsp;Alessio Cremonesi ,&nbsp;Pietro Vernazza ,&nbsp;Philipp Kohler ,&nbsp;Christian R. Kahlert","doi":"10.1016/j.jim.2024.113800","DOIUrl":"10.1016/j.jim.2024.113800","url":null,"abstract":"<div><h3>Background and aims</h3><div>Dried blood spots (DBS) have been proposed as a cost-effective surveillance method for population-wide screening of SARS-CoV-2 immunity but sensitivity of DBS based on self-collected DBS samples is unknown. To evaluate the success of vaccination strategies, it is necessary to differentiate vaccination from natural infection. Therefore, a test for antibodies against the viral nucleocapsid protein (anti-N) is desirable.</div></div><div><h3>Materials and methods</h3><div>In our prospectively followed cohort of healthcare workers (HCW) in eastern Switzerland, we assessed SARS-CoV-2-anti-N-seroprevalence using DBS on a biweekly basis from March to September 2020. Phlebotomy samples were collected in March and September and tested for anti-N-seropositivity, as well as SARS-CoV-2 spike antibodies for quantitative validation. Venous antibody testing was compared with DBS results for anti-N using the Roche Elecsys electro-chemiluminescence immunoassay.</div></div><div><h3>Results</h3><div>792 HCW (median age 38.3 years) were included, 35 (4.4 %) were SARS-CoV-2-anti-N-seropositive. Of 43 matching DBS, 25 tested positive for anti-N, accounting for a sensitivity of 58.1 % (95 %CI 43.3–71.6 %). We found a significant correlation of anti-N from DBS with results from phlebotomy samples (<em>r</em> = 0.77;<em>p</em> &lt; 0.0001), with higher levels being associated with a higher true-positive rate. Anti-N in DBS correlated significantly with quantitatively validated anti-S obtained from serum (<em>r</em> = 0.67;<em>p</em> &lt; 0.0001).</div></div><div><h3>Conclusion</h3><div>Although home DBS collection was feasible in a larger cohort and we found a high correlation between anti-N detection in DBS and phlebotomy samples, the sensitivity of self-collected DBS samples was significantly impaired for the Roche Elecsys anti-N assay. Therefore, we cannot recommend this method for DBS when testing from venous blood is possible.</div></div>","PeriodicalId":16000,"journal":{"name":"Journal of immunological methods","volume":"536 ","pages":"Article 113800"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adaptation of the in vivo respiratory burst assay for fathead minnow larvae (Pimephales promelas) 黑头鲦鱼(Pimephales promelas)幼虫体内呼吸爆发试验的适应性。
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2025-01-01 DOI: 10.1016/j.jim.2024.113797
Nicole Kooij, Tisha C. King-Heiden
Initial innate immune responses such as the respiratory burst response of phagocytes present the first line of defense in response to exposure to pathogens. Several respiratory burst assays have been developed in mammals, cell cultures, and whole zebrafish embryos as a reliable indicator of the innate immune response of a host, and these assays are being used to screen various environmental contaminants for their immunotoxic potential. While zebrafish are a common laboratory fish used in toxicology studies geared towards human health effects, fathead minnows are commonly used as an ecotoxicological indicator species for North America. In this technical note, we describe how we adapted the zebrafish in vivo respiratory burst assay for use in fathead minnow larvae. This assay provides promising expansion of using in vivo respiratory burst responses in different species of larval fish for future comparative immunotoxicity assays, as well as laying the groundwork for studies that can better define the development of the innate and adaptive immune responses of fathead minnow larvae.
最初的先天免疫反应,如吞噬细胞的呼吸爆发反应,是暴露于病原体时的第一道防线。已经在哺乳动物、细胞培养物和整个斑马鱼胚胎中开发了几种呼吸爆发试验,作为宿主先天免疫反应的可靠指标,这些试验被用于筛选各种环境污染物的免疫毒性潜力。虽然斑马鱼是针对人类健康影响的毒理学研究中常用的实验鱼,但在北美,黑头鲦鱼通常被用作生态毒理学指示物种。在这篇技术笔记中,我们描述了我们如何将斑马鱼体内呼吸爆发试验用于黑头鲦鱼幼虫。该实验为今后在不同鱼类幼鱼体内进行呼吸爆发反应的比较免疫毒性试验提供了广阔的应用前景,并为更好地定义黑头鲦鱼幼鱼先天和适应性免疫反应的发展奠定了基础。
{"title":"Adaptation of the in vivo respiratory burst assay for fathead minnow larvae (Pimephales promelas)","authors":"Nicole Kooij,&nbsp;Tisha C. King-Heiden","doi":"10.1016/j.jim.2024.113797","DOIUrl":"10.1016/j.jim.2024.113797","url":null,"abstract":"<div><div>Initial innate immune responses such as the respiratory burst response of phagocytes present the first line of defense in response to exposure to pathogens. Several respiratory burst assays have been developed in mammals, cell cultures, and whole zebrafish embryos as a reliable indicator of the innate immune response of a host, and these assays are being used to screen various environmental contaminants for their immunotoxic potential. While zebrafish are a common laboratory fish used in toxicology studies geared towards human health effects, fathead minnows are commonly used as an ecotoxicological indicator species for North America. In this technical note, we describe how we adapted the zebrafish <em>in vivo</em> respiratory burst assay for use in fathead minnow larvae. This assay provides promising expansion of using <em>in vivo</em> respiratory burst responses in different species of larval fish for future comparative immunotoxicity assays, as well as laying the groundwork for studies that can better define the development of the innate and adaptive immune responses of fathead minnow larvae.</div></div>","PeriodicalId":16000,"journal":{"name":"Journal of immunological methods","volume":"536 ","pages":"Article 113797"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Natural cross-reactive anti-SARS-CoV-2 antibodies in avian egg yolk 禽蛋黄中的天然交叉反应抗 SARS-CoV-2 抗体
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2025-01-01 DOI: 10.1016/j.jim.2024.113798
Gholamreza Nikbakht Brujeni, Pouya Houshmand, Shervin Sadafian, Reza Rezaei
Since the beginning of the 21st century, the Coronaviridiae family has caused several life-threatening outbreaks in the world. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the cause of the latest Coronaviridiae-related outbreak, is still a major health issue worldwide. Prevention, diagnosis, and therapeutic actions are the most important strategies to mitigate the spread of the COVID-19 pandemic. Among therapeutics, specific antibodies play a crucial role in controlling the symptoms of patients and preventing others from becoming infected. Here, we have introduced the avian egg yolk as a natural source of cross-reactive anti-SARS-CoV-2 immunoglobulin Y. ELISA, dot blot and western blot were used to identify natural anti-SARS-CoV-2 IgY in the egg yolk of different species of birds. Also, bioinformatics analysis was performed to investigate the possible causes of the presence of these natural antibodies in the egg yolks. The results of blotting and ELISA assays demonstrated that the egg yolk-derived antibodies could identify and bind to the different subunits of SARS-CoV-2. Substantial concentrations of neutralizing antibodies against SARS-CoV-2 were also detected in the egg yolk. In addition, bioinformatics analysis showed structural similarities between the components of infectious bronchitis virus, SARS-CoV-2, and other members of the Coronaviridiae family. It seems that egg yolk can be used as a natural, inexpensive, and accessible source of anti-SARS-CoV-2 antibodies. Diverse diagnostic and therapeutic potentials for avian egg yolk-derived anti-SARS-CoV-2 antibodies are imagined.
自21世纪初以来,冠状病毒家族在世界上引发了几次危及生命的疫情。严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)是导致最新冠状病毒相关疫情的原因,仍然是全球主要的卫生问题。预防、诊断和治疗行动是缓解COVID-19大流行传播的最重要战略。在治疗方法中,特异性抗体在控制患者症状和防止他人感染方面起着至关重要的作用。本文介绍了禽类蛋黄作为交叉反应性抗sars - cov -2免疫球蛋白y的天然来源,采用ELISA、dot blot和western blot方法对不同种鸟蛋黄中的天然抗sars - cov -2免疫球蛋白y进行了鉴定。此外,还进行了生物信息学分析,以探讨这些天然抗体在蛋黄中存在的可能原因。印迹和酶联免疫吸附试验结果表明,蛋黄源性抗体能够识别和结合SARS-CoV-2的不同亚基。在蛋黄中还检测到大量浓度的针对SARS-CoV-2的中和抗体。此外,生物信息学分析显示传染性支气管炎病毒、SARS-CoV-2和其他冠状病毒科成员的成分结构相似。蛋黄似乎可以作为抗sars - cov -2抗体的天然、廉价和可获得的来源。鸟蛋黄衍生的抗sars - cov -2抗体具有多种诊断和治疗潜力。
{"title":"Natural cross-reactive anti-SARS-CoV-2 antibodies in avian egg yolk","authors":"Gholamreza Nikbakht Brujeni,&nbsp;Pouya Houshmand,&nbsp;Shervin Sadafian,&nbsp;Reza Rezaei","doi":"10.1016/j.jim.2024.113798","DOIUrl":"10.1016/j.jim.2024.113798","url":null,"abstract":"<div><div>Since the beginning of the 21st century, the <em>Coronaviridiae</em> family has caused several life-threatening outbreaks in the world. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the cause of the latest <em>Coronaviridiae</em>-related outbreak, is still a major health issue worldwide. Prevention, diagnosis, and therapeutic actions are the most important strategies to mitigate the spread of the COVID-19 pandemic. Among therapeutics, specific antibodies play a crucial role in controlling the symptoms of patients and preventing others from becoming infected. Here, we have introduced the avian egg yolk as a natural source of cross-reactive anti-SARS-CoV-2 immunoglobulin Y. ELISA, dot blot and western blot were used to identify natural anti-SARS-CoV-2 IgY in the egg yolk of different species of birds. Also, bioinformatics analysis was performed to investigate the possible causes of the presence of these natural antibodies in the egg yolks. The results of blotting and ELISA assays demonstrated that the egg yolk-derived antibodies could identify and bind to the different subunits of SARS-CoV-2. Substantial concentrations of neutralizing antibodies against SARS-CoV-2 were also detected in the egg yolk. In addition, bioinformatics analysis showed structural similarities between the components of infectious bronchitis virus, SARS-CoV-2, and other members of the <em>Coronaviridiae</em> family. It seems that egg yolk can be used as a natural, inexpensive, and accessible source of anti-SARS-CoV-2 antibodies. Diverse diagnostic and therapeutic potentials for avian egg yolk-derived anti-SARS-CoV-2 antibodies are imagined.</div></div>","PeriodicalId":16000,"journal":{"name":"Journal of immunological methods","volume":"536 ","pages":"Article 113798"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of the linear Fc-binding epitope on the bovine IgG1 Fc receptor of (boFcγRI) using synthetic peptides 用合成肽鉴定牛IgG1 Fc受体(boFcγRI)上的线性Fc结合表位。
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2025-01-01 DOI: 10.1016/j.jim.2024.113799
Qingmei Li , Ge Li , Xun Wang , Ruining Wang , Jifei Yang , Junqing Guo , Gaiping Zhang

Background

Bovine IgG1 Fc receptor (boFcγRI) is a homologue to human FcγRI (CD64) that has three extracellular Ig-like domains and can bind bovine IgG1 with high affinity. Identification of the linear epitope for Fc-binding on boFcγRI provides new insights for the IgG-Fcγ interaction and FcγR-targeting drugs development.

Methods

The boFcγRI molecules were expressed on cell surface of the boFcγRI -transfected COS-7 cells. The extracellular domain of boFcγRI was expressed in Escherichia coli (E. coli) BL21, and the soluble boFcγRI was purified by Ni-chelation chromatography followed by refolding. To identify the Fc-binding epitope on the boFcγRI, peptides derived from the membrane-distal extracellular domain (EC2) of boFcγRI were synthesized and conjugated to a carrier protein of IgG-free bovine serum albumin (BSA). Binding of bovine IgG1 to the different peptides was tested by Dot-blot assay, and the peptide showing maximal IgG-binding was further modified by truncation and mutation. The inhibition effect of the Fc-binding peptide was determined by competitive ELISA and Fc-rosetting inhibition assay, respectively.

Results

The minimal effective peptide TNLSHNGI corresponding to the sequence 142–149 of boFcγRI was found to bind bovine IgG1 specifically in Dot-blot suggesting it represents a linear ligand-binding epitope located in the putative E-F loop of the EC2 domain on the receptor. Mutation analysis of the peptide showed that the residues of Thr142, Asn143, Leu144, Gly148 and Ile149 within the linear epitope are critical for IgG1-binding. The Fc-binding peptide inhibited bovine IgG1 binding to the soluble recombinant protein of boFcγRII with IC50 of 20.27 μmol/L, and inhibited the rosette formation of bovine IgG1-sensitized RBCs on the boFcγRI transfected cells with IC50 of 86.75 μmol/L.

Conclusions

The linear epitope for Fc-binding as well as its crucial residues of EC2 domain on boFcγRI was identified using synthetic peptides. The Fc-binding peptide showed well capability of regulating boFcγRI-IgG1 interaction on cell surface.
背景:牛 IgG1 Fc 受体(boFcγRI)是人 FcγRI (CD64)的同源物,具有三个细胞外 Ig 样结构域,能与牛 IgG1 高亲和力结合。鉴定 boFcγRI 上 Fc 结合的线性表位为 IgG-Fcγ 相互作用和 FcγR 靶向药物的开发提供了新的见解:方法:在转染 COS-7 细胞的细胞表面表达 boFcγRI 分子。在大肠杆菌(E. coli)BL21 中表达 boFcγRI 的胞外结构域,并通过镍螯合色谱法纯化可溶性 boFcγRI 后进行重折叠。为了确定 boFcγRI 上的 Fc 结合表位,合成了来自 boFcγRI 膜远端胞外结构域(EC2)的多肽,并将其与不含 IgG 的牛血清白蛋白(BSA)载体蛋白结合。通过点印迹试验检测了牛 IgG1 与不同多肽的结合情况,并通过截短和突变对显示出最大 IgG 结合力的多肽进行了进一步修饰。Fc 结合肽的抑制效果分别通过竞争性酶联免疫吸附试验(Competitive ELISA)和 Fc 漂移抑制试验(Fc-rosetting inhibition assay)进行测定:结果:与 boFcγRI 142-149 序列相对应的最小有效肽 TNLSHNGI 在 Dot-blot 中与牛 IgG1 特异性结合,表明它代表了位于受体 EC2 结构域假定 E-F 环的线性配体结合表位。对该肽的突变分析表明,线性表位中的 Thr142、Asn143、Leu144、Gly148 和 Ile149 残基对 IgG1 结合至关重要。该 Fc 结合肽可抑制牛 IgG1 与 boFcγRII 可溶性重组蛋白的结合,IC50 为 20.27 μmol/L,并可抑制牛 IgG1 致敏 RBC 在 boFcγRI 转染细胞上的莲座形成,IC50 为 86.75 μmol/L:结论:利用合成肽鉴定了boFcγRI上EC2结构域的Fc结合线性表位及其关键残基。该 Fc 结合肽具有良好的调节细胞表面 boFcγRI-IgG1 相互作用的能力。
{"title":"Identification of the linear Fc-binding epitope on the bovine IgG1 Fc receptor of (boFcγRI) using synthetic peptides","authors":"Qingmei Li ,&nbsp;Ge Li ,&nbsp;Xun Wang ,&nbsp;Ruining Wang ,&nbsp;Jifei Yang ,&nbsp;Junqing Guo ,&nbsp;Gaiping Zhang","doi":"10.1016/j.jim.2024.113799","DOIUrl":"10.1016/j.jim.2024.113799","url":null,"abstract":"<div><h3>Background</h3><div>Bovine IgG1 Fc receptor (boFcγRI) is a homologue to human FcγRI (CD64) that has three extracellular Ig-like domains and can bind bovine IgG1 with high affinity. Identification of the linear epitope for Fc-binding on boFcγRI provides new insights for the IgG-Fcγ interaction and FcγR-targeting drugs development.</div></div><div><h3>Methods</h3><div>The boFcγRI molecules were expressed on cell surface of the boFcγRI -transfected COS-7 cells. The extracellular domain of boFcγRI was expressed in <em>Escherichia coli</em> (<em>E. coli</em>) BL21, and the soluble boFcγRI was purified by Ni-chelation chromatography followed by refolding. To identify the Fc-binding epitope on the boFcγRI, peptides derived from the membrane-distal extracellular domain (EC2) of boFcγRI were synthesized and conjugated to a carrier protein of IgG-free bovine serum albumin (BSA). Binding of bovine IgG1 to the different peptides was tested by Dot-blot assay, and the peptide showing maximal IgG-binding was further modified by truncation and mutation. The inhibition effect of the Fc-binding peptide was determined by competitive ELISA and Fc-rosetting inhibition assay, respectively.</div></div><div><h3>Results</h3><div>The minimal effective peptide TNLSHNGI corresponding to the sequence 142–149 of boFcγRI was found to bind bovine IgG1 specifically in Dot-blot suggesting it represents a linear ligand-binding epitope located in the putative E-F loop of the EC2 domain on the receptor. Mutation analysis of the peptide showed that the residues of Thr<sup>142</sup>, Asn<sup>143</sup>, Leu<sup>144</sup>, Gly<sup>148</sup> and Ile<sup>149</sup> within the linear epitope are critical for IgG1-binding. The Fc-binding peptide inhibited bovine IgG1 binding to the soluble recombinant protein of boFcγRII with IC<sub>50</sub> of 20.27 μmol/L, and inhibited the rosette formation of bovine IgG1-sensitized RBCs on the boFcγRI transfected cells with IC<sub>50</sub> of 86.75 μmol/L.</div></div><div><h3>Conclusions</h3><div>The linear epitope for Fc-binding as well as its crucial residues of EC2 domain on boFcγRI was identified using synthetic peptides. The Fc-binding peptide showed well capability of regulating boFcγRI-IgG1 interaction on cell surface.</div></div>","PeriodicalId":16000,"journal":{"name":"Journal of immunological methods","volume":"536 ","pages":"Article 113799"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization of an IL-8 cleavage inhibition assay to determine the functionality of anti-SpyCEP antibodies in human sera IL-8切割抑制实验的表征,以确定人血清中抗spycep抗体的功能。
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2025-01-01 DOI: 10.1016/j.jim.2024.113786
Luisa Massai , Martina Carducci , Luca Rovetini , Aimee Paterson , Alana Whitcombe , Reuben McGregor , Natalie Lorenz , Alexander J. Keeley , Thushan I. de Silva , Julie Bennett , Francesco Berlanda Scorza , Miren Iturriza , Nicole J. Moreland , Danilo G. Moriel , Omar Rossi
Exposure to Group A Streptococcus leads to a broad spectrum of disease and sequelae, as the bacterium employs a wide range of virulence factors to facilitate colonization of the host, propagation and onward transmission, disrupting both innate and adaptive immune responses. The protease SpyCEP has a crucial role in contributing to bacterial immune evasion by impairing neutrophil recruitment and killing of bacteria through the cleavage of interleukin-8 (IL-8). Given this critical function, SpyCEP represents a key vaccine antigen and quantifying functional anti-SpyCEP antibodies represents not only an important marker of vaccine efficacy, but also a tool to dissect the natural immune response. Here, we report the development and characterization of an IL-8 cleavage inhibition assay to measure the function of anti-SpyCEP antibodies in human sera. The assay was demonstrated to be sensitive, highly specific, linear and reproducible, and suitable for evaluating the function of anti-SpyCEP antibodies induced in humans in vaccine clinical trials and in observational studies of natural immunity.
暴露于A群链球菌会导致广泛的疾病和后遗症,因为这种细菌利用广泛的毒力因子来促进宿主的定植、繁殖和向前传播,破坏先天和适应性免疫反应。蛋白酶SpyCEP通过破坏白细胞介素-8 (IL-8)的分裂而抑制中性粒细胞的募集和杀死细菌,在细菌免疫逃避中起着至关重要的作用。鉴于这一关键功能,SpyCEP是一种关键的疫苗抗原,定量测定功能性抗SpyCEP抗体不仅是疫苗有效性的重要标志,也是解剖自然免疫反应的工具。在这里,我们报道了IL-8切割抑制实验的发展和表征,以测量人血清中抗spycep抗体的功能。结果表明,该方法灵敏度高、特异性高、线性和可重复性好,适用于评估疫苗临床试验和自然免疫观察性研究中人体诱导的抗spycep抗体的功能。
{"title":"Characterization of an IL-8 cleavage inhibition assay to determine the functionality of anti-SpyCEP antibodies in human sera","authors":"Luisa Massai ,&nbsp;Martina Carducci ,&nbsp;Luca Rovetini ,&nbsp;Aimee Paterson ,&nbsp;Alana Whitcombe ,&nbsp;Reuben McGregor ,&nbsp;Natalie Lorenz ,&nbsp;Alexander J. Keeley ,&nbsp;Thushan I. de Silva ,&nbsp;Julie Bennett ,&nbsp;Francesco Berlanda Scorza ,&nbsp;Miren Iturriza ,&nbsp;Nicole J. Moreland ,&nbsp;Danilo G. Moriel ,&nbsp;Omar Rossi","doi":"10.1016/j.jim.2024.113786","DOIUrl":"10.1016/j.jim.2024.113786","url":null,"abstract":"<div><div>Exposure to Group A Streptococcus leads to a broad spectrum of disease and sequelae, as the bacterium employs a wide range of virulence factors to facilitate colonization of the host, propagation and onward transmission, disrupting both innate and adaptive immune responses. The protease SpyCEP has a crucial role in contributing to bacterial immune evasion by impairing neutrophil recruitment and killing of bacteria through the cleavage of interleukin-8 (IL-8). Given this critical function, SpyCEP represents a key vaccine antigen and quantifying functional anti-SpyCEP antibodies represents not only an important marker of vaccine efficacy, but also a tool to dissect the natural immune response. Here, we report the development and characterization of an IL-8 cleavage inhibition assay to measure the function of anti-SpyCEP antibodies in human sera. The assay was demonstrated to be sensitive, highly specific, linear and reproducible, and suitable for evaluating the function of anti-SpyCEP antibodies induced in humans in vaccine clinical trials and in observational studies of natural immunity.</div></div>","PeriodicalId":16000,"journal":{"name":"Journal of immunological methods","volume":"536 ","pages":"Article 113786"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel panel of peptides with diagnostic potential for serological identification of Borrelia burgdorferi sensu stricto, B. garinii and B. afzelii in human sera 一组具有诊断潜力的新型多肽可用于人类血清中严格感伯氏疏螺旋体、B. garinii和B. afzelii的血清学鉴定。
IF 1.6 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS Pub Date : 2025-01-01 DOI: 10.1016/j.jim.2025.113802
Antonio C.G. Foddai , Peter Wilhelmsson , Per-Eric Lindgren , Jeremy M. Sternberg , Alan S. Bowman
A novel panel of peptide for serological identification of Borrelia burgdoferi sensu stricto, Borrelia garinii and Borrelia afzelii was developed and assessed in this study. The diagnostic algorithm of the novel test was initially trained testing 10 US human sera including 3 early-stage and 3 late-stage Lyme disease positive sera, 2 sera positive for Babesia and 2 sera positive for Syphilis, all purchased from a private biorepository. Findings were then corroborated testing (a) 33 additional EU follow-up positive sera from seroconverted patients bitten by ticks that tested positive for B. burgdorferi sensu stricto (No 2), Borrelia garinii (No 14), Borrelia afzelii (No 15) Borrelia valaisiana (No 2), and (b) 40 negative sera from US healthy donors. Results of preliminary US sera testing showed successful detection of IgM and IgG antibodies and correct identification of Borrelia burgdorferi sensu stricto in all the samples tested. Analysis of EU follow-up sera showed much higher sensitivity and accuracy when IgM and IgG were tested combined together rather than separately. Sensitivity and accuracy in species identification of the anti-IgM + IgG multiplex peptide ELISA was 93.5 % and 96.5 % respectively; lower test performance was observed when IgM (i.e. sensitivity = 58.1 %; correct identification = 88.8 %) and IgG testing (i.e. sensitivity = 74.1 %; correct identification = 96.5 %) were carried out separately. Overall specificity of the anti-IgM, anti-IgG and anti-IgM + IgG multiplex peptide ELISA calculated on a total number of 46 negative sera included in this study was 91.3 %, 95.6 and 93.4 %, respectively.
本研究开发了一种新的用于严格感伯氏疏螺旋体、加里氏疏螺旋体和阿泽利氏疏螺旋体血清学鉴定的肽组。该新型检测方法的诊断算法经过初步训练,检测了10份美国人血清,包括3份早期莱姆病阳性血清和3份晚期莱姆病阳性血清,2份巴贝斯虫阳性血清和2份梅毒阳性血清,均购自一家私人生物库。随后,研究结果证实了以下检测结果:(a) 33份来自被蜱虫叮咬的血清转化患者的欧盟随访阳性血清,这些患者的严格感伯氏疏螺旋体(2号)、加里尼伯氏疏螺旋体(14号)、阿夫氏疏螺旋体(15号)、瓦莱西伯氏疏螺旋体(2号)检测呈阳性,以及(b) 40份来自美国健康供体的阴性血清。美国初步血清检测结果显示,所有检测样本均成功检测到IgM和IgG抗体,并正确鉴定出严格感伯氏疏螺旋体。结果表明,IgM和IgG联合检测比单独检测更具有敏感性和准确性。抗igm + IgG复合肽ELISA法鉴定种属的灵敏度和准确度分别为93.5 %和96.5 %;IgM(即敏感性 = 58.1 %;正确鉴别 = 88.8 %)和IgG检测(即灵敏度 = 74.1 %;正确鉴别 = 96.5 %)分别进行。本研究共纳入46份阴性血清,计算抗igm、抗IgG和抗igm + IgG复合肽ELISA的总特异性分别为91.3 %、95.6%和93.4 %。
{"title":"A novel panel of peptides with diagnostic potential for serological identification of Borrelia burgdorferi sensu stricto, B. garinii and B. afzelii in human sera","authors":"Antonio C.G. Foddai ,&nbsp;Peter Wilhelmsson ,&nbsp;Per-Eric Lindgren ,&nbsp;Jeremy M. Sternberg ,&nbsp;Alan S. Bowman","doi":"10.1016/j.jim.2025.113802","DOIUrl":"10.1016/j.jim.2025.113802","url":null,"abstract":"<div><div>A novel panel of peptide for serological identification of <em>Borrelia burgdoferi</em> sensu stricto, <em>Borrelia garinii</em> and <em>Borrelia afzelii</em> was developed and assessed in this study. The diagnostic algorithm of the novel test was initially trained testing 10 US human sera including 3 early-stage and 3 late-stage Lyme disease positive sera, 2 sera positive for Babesia and 2 sera positive for Syphilis, all purchased from a private biorepository. Findings were then corroborated testing (a) 33 additional EU follow-up positive sera from seroconverted patients bitten by ticks that tested positive for <em>B. burgdorferi</em> sensu stricto (No 2), <em>Borrelia garinii</em> (No 14), <em>Borrelia afzelii</em> (No 15) <em>Borrelia valaisiana</em> (No 2), and (b) 40 negative sera from US healthy donors. Results of preliminary US sera testing showed successful detection of IgM and IgG antibodies and correct identification of <em>Borrelia burgdorferi</em> sensu stricto in all the samples tested. Analysis of EU follow-up sera showed much higher sensitivity and accuracy when IgM and IgG were tested combined together rather than separately. Sensitivity and accuracy in species identification of the anti-IgM + IgG multiplex peptide ELISA was 93.5 % and 96.5 % respectively; lower test performance was observed when IgM (i.e. sensitivity = 58.1 %; correct identification = 88.8 %) and IgG testing (i.e. sensitivity = 74.1 %; correct identification = 96.5 %) were carried out separately. Overall specificity of the anti-IgM, anti-IgG and anti-IgM + IgG multiplex peptide ELISA calculated on a total number of 46 negative sera included in this study was 91.3 %, 95.6 and 93.4 %, respectively.</div></div>","PeriodicalId":16000,"journal":{"name":"Journal of immunological methods","volume":"536 ","pages":"Article 113802"},"PeriodicalIF":1.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142965567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of immunological methods
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1